A phase 2 trial evaluating CS-1103 in participants with methamphetamine use disorder is expected to begin in the first quarter of 2026. The Food and Drug Administration (FDA) has granted Fast Track ...
Unlike with opioids, there is no medication to suppress cravings for meth and other stimulants. As use soars, hundreds of clinics are trying a radically different approach. Six months after a doctor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results